Evidence map›Paper›PMID 36456996›Full record

ArticleJournal of nanobiotechnology2022

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect.

Xuan Sha, Yue Dai, Lijuan Chong, Min Wei, Mengyuan Xing, Chun Zhang, Jingjing Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. How Advanced Is Nanomedicine for Atherosclerosis?International journal of nanomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xuan ShaSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Yue DaiSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Lijuan ChongSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Min WeiSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Mengyuan XingSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Chun ZhangSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Jingjing LiSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China. qingchao0124@163.com.
Xuzhou Medical College · CN

Funding

Natural Science Foundation of Jiangsu Province BK20221391Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX21_2737Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX22_2958Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX22_2972Six one project of Jiangsu Province LGY2018083the Peak of Six Talents of Jiangsu Province WSN-112
6 · The paper itself

Abstract

Macrophages participate in many links in the pathological process of atherosclerosis (AS) and the regulation of influence of macrophages at the molecular level might be a new avenue for AS treatment. For this aim, the macrophage membrane biomimetic nanoparticles, derived from macrophage membrane coated SHP1i-loaded liposome NPs (MM@Lips-SHP1i) was designed. Due to the reservation of intrinsic membrane proteins and function from macrophages, the biomimic nanoparticles could effectively evade clearance by the immune system, prolong blood circulation time and actively tend and aggregate to atherosclerotic plaques. More importantly, in the plaque area, MM@Lips-SHP1i nanoparticles could compete with macrophages in vivo to bind with oxidized low-density lipoprotein (oxLDL) and lipopolysaccharide (LPS), reduce uptake of new lipids by macrophages, reduce foam cell formation, and inhibit the expression of pro-inflammatory cytokines. In addition, small molecule inhibitor of SHP-1, the downstream effector molecule of CD47 loaded in macrophage membrane biomimetic nanoparticles could interrupt CD47-SIRPα signal transduction in monocytes and macrophages, thereby enhancing the efferocytosis of macrophages, inhibiting the progression of plaque, achieving synergistic treatment of atherosclerosis. This work focuses on the key process in the formation of AS, macrophage foaming and chronic inflammation, and is based on the fact that macrophage membrane biomimetic nanoparticles can preserve the key surface proteins of macrophages closely related to the formation of AS, providing a new avenue to inhibit the progression of AS by utilizing the biological characteristics of macrophage membrane in macrophage membrane biomimetic nanoparticles.

Indexed as

AtherosclerosisNanoparticlesPlaque, AtheroscleroticBiomimeticsCD47 AntigenHumansMacrophagesMembrane ProteinsCD47 AntigenMembrane ProteinsAtherosclerosisBiomimetic nanoparticlesEfferocytosisMacrophage membraneSynergistic treatment

Identifiers

PMID36456996
PMCPMC9714205
OpenAlexW4310496112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.